New Cancer Research Targeted Kinase Degradation
Researchers developed a way to eliminate cancer-promoting enzymes that often evade traditional drug therapy.
Updated on Sept. 29, 2026 in Cancer
A research team led by Conery has introduced a new method to eliminate target kinases involved in cancer, offering a potential path forward for treatments where standard inhibitors fail. This development is significant for lung cancer patients who face recurring disease after current therapies stop working.
Why it matters
Many cancers return because kinases undergo amino-acid changes that render traditional inhibitors ineffective. This approach seeks to bypass such resistance by destroying the target kinase rather than merely blocking its activity.
A report published in Nature on September 29, 2026, details a new method to eliminate target kinases. The study contrasts this degradation strategy with the 28 FDA-approved kinase inhibitors currently used for nine molecular subsets of lung cancer.
The players
Conery
Lead researcher who reported a method for eliminating target kinases in cancer treatment.
US Food and Drug Administration
The federal agency responsible for regulating the 28 kinase inhibitors currently used in clinical care.
The details
Traditional kinase inhibitors function by blocking the activity of enzymes that drive tumor growth. In contrast, this new approach aims to eliminate the target kinase entirely. By removing the enzyme instead of just inhibiting its function, the method may overcome the resistance that occurs when cancer cells change their amino-acid residues at the active site.
Timeline
September 29, 2026: Research report published in Nature.
Health Landscape
The standard of care for several cancers relies on targeted kinase inhibition to block specific enzyme activity. This new research represents a shift toward protein degradation, which aims to address the limitations of existing therapies that often fail due to drug resistance.
If you or a loved one are undergoing treatment for lung cancer, this research highlights why clinicians sometimes observe resistance to therapy over time. Any questions about how resistance occurs in your specific cancer diagnosis are worth discussing with your oncologist.
The takeaway
The study suggests that future cancer therapies might move beyond simple inhibition to actively eliminate rogue proteins. Patients should monitor future clinical developments in kinase degradation as a potential avenue for addressing therapy-resistant cancers.
Further reading
For more information on the current state of oncology research, visit the Cancer section.
Source note: This article includes information reported by Nature.
